NovellusDx collaborates with Primetech as an Exclusive Supplier in Japan
Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform
Shots:
- NovellusDx will provide its functional genomics assay FACT (Functional Annotation for Cancer Treatment) to Primetech, for pre-clinical market with sales, marketing and research/technical support in Japan exclusively
- FACT has capability to determine trial outcomes in patients, now this system will help in developing anti-cancer drugs and mechanism of action
- Japan is the first territory where NovellusDx will be marketing as agent agreement
